Viscosupplementation Market, by Treatment (Single Injection Treatment Cycle, Three Injection Treatment Cycle, and Five Injection Treatment Cycle), by Application (Knee Osteoarthritis, Hip Osteoarthritis, and Others), and by Region (North America, Latin Am

Viscosupplementation Market, by Treatment (Single Injection Treatment Cycle, Three Injection Treatment Cycle, and Five Injection Treatment Cycle), by Application (Knee Osteoarthritis, Hip Osteoarthritis, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Viscosupplementation is a treatment that helps in reducing the joint pain, and improves the functional condition of the osteoarthritic joint. It involves the injection of a thick fluid called hyaluronic acid into the knee. Hyaluronic acid (HA) is found in the synovial fluid that lubricates the cartilage surfaces and protects the joints from shock. It greases joints so that bones can move freely and discomfort is reduced. People with osteoarthritis have reduced levels of hyaluronic acid in their joints, which causes pain. The injected gel acts as a cushion and greases up the joints. Hyaluronic acid binds to a variety of proteins, allowing it to make ligaments resistant to pressure. Osteoarthritis is the most common type of arthritis characterized by loss of function and degeneration of cartilage and tissues that cover the ends of the bones in a joint.

Market Dynamics

The increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market growth. Increasing adoption of inorganic strategies by key players in market such as acquisitions is expected to drive market growth over the forecast period. Moreover, the onset of the condition is mostly after 30 years of age, which may progress to develop into a disability after 10 years of diagnosis, thus, the rise in geriatrics population in turn, will lead to a rise in the incidence of obesity and osteoarthritis. For instance, according to the WHO (world health organization), as on 4 October, 2021, the proportion of the world's population over 60 years will nearly double from 12% to 22%. By 2050, the world’s population of people aged 60 years and older will be nearly 2.1 billion.

Key features of the study:

• This report provides an in-depth analysis of the global viscosupplementation market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global viscosupplementation market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., OrthogenRx, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global viscosupplementation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viscosupplementation market

Detailed Segmentation:

• Global Viscosupplementation Market, By Treatment:
• Single Injection Treatment Cycle
• Three Injection Treatment Cycle
• Five Injection Treatment Cycle
• Global Viscosupplementation Market, By Application:
• Knee Osteoarthritis
• Hip Osteoarthritis
• Others
• Global Viscosupplementation Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Anika Therapeutics Inc*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Seikagaku Corporation
• Ferring Pharmaceuticals
• Bioventus
• Fidia Farmaceutici S.P.A.
• Mylan N.V.
• Sanofi S.A.
• ORTHOGENRX
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson

“*” marked represents similar segmentation in other categories in the respective section.